ArticleFrontiers in medicine2026
Real-world effectiveness of MiSight 1 Day contact lenses in Taiwanese children: a multicenter retrospective study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the real-world effectiveness of MiSight 1 Day soft contact lenses for myopia control in Taiwanese children using age-, sex-, and percentile-matched axial length (AL) references. Methods: Retrospective multicenter study across 23 Universal Eye Center clinics. Children aged 6-18 years who initiated MiSight between October 2020 and July 2022 and completed ≥12 months of follow-up were included. Spherical equivalent (SE) and AL were extracted from clinical records and annualized. Observed AL change was compared with matched Taiwanese normative percentiles to estimate axial suppression. Subgroups included age, baseline AL percentile, and prior treatment history. Results: A total of 368 eyes from 368 patients were analyzed (mean age 11.8 ± 2.3 years; 52% female; mean follow-up 19.2 ± 5.0 months). Mean SE progression was -0.41 ± 0.42 D/year. Mean AL elongation was 0.17 mm/year, corresponding to a mean AL suppression of 0.06 mm/year relative to matched Taiwanese norms. Visual performance was favorable, with 98% achieving ≥20/25. Outcomes were similar across prior treatment groups, including previous atropine or orthokeratology exposure. Conclusion: In routine Taiwanese practice, MiSight 1 Day provided meaningful myopia control and maintained good vision. AL growth was reduced by 27% versus matched normative expectations. These findings support the translational effectiveness of MiSight and emphasize the value of regional normative benchmarks for clinical interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.